Plus   Neg

Exact Sciences Sees Q4 Revenue Above View

Exact Sciences Corp. (EXAS) said that it expects revenue to be between $464.5 million and $467.5 million for the fourth quarter ended December 31, 2020. Analysts polled by Thomson Reuters expect the company to report revenues of $431.18 million for the fourth-quarter. Analysts' estimates typically exclude special items.

The company expects fourth-quarter Screening revenue to be in the range of $249 million - $250 million, an increase of 9 percent from last year. It projects COVID-19 testing revenue between $98.5 million and $99.5 million for the fourth-quarter.

For the twelve-month period ended December 31, 2020, the company projects total revenue to be between $1.490 billion and $1.493 billion, COVID-19 testing revenue of $235 million - $236 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT